This study aimed to evaluate the efficacy and safety of oral antibacterial treatment with fluoroquinilone for acute uncomplicated
pyelonephritis Thirteen female patients with acute uncomplicated
pyelonephritis were treated with oral fluoroquinilone (
ciprofloxacin; CPFX). They received 200 mg of the
drug three times a day while febrile (3-5 days). Once they become afebrile, the same dose of the
drug, given twice a day, was given for another 9-11 days. The mean duration of the course of CPFX was 14 days. Symptoms were evaluated, and laboratory examinations, including urine culture and measurement of the minimal inhibitory concentration (MIC) of CPFX were conducted before treatment, and 3, 7, 14, 21, and/or 28 days after the initiation of the treatment. Of the 13 patients, only 5 needed to be hospitalized, and the period of hospitalization was only a few days. On the 14th day after the commencement of treatment, bacteriologic and clinical cure rates were 100%. Escherichia coli was the most common uropathogen, being isolated from the urine of 8 patients. No clinical relapse of the disease was found during a follow-up period of up to 4 weeks. The patients tolerated the
drug well without developing any serious adverse effects. Oral antimicrobial
chemotherapy with
fluoroquinolone, given on an outpatient or short-term hospitalization basis, achieved satisfactory bacteriological and clinical outcomes in the treatment of acute uncomplicated
pyelonephritis. This treatment regimen is indicated for patients with this disease who are not in a serious condition with complications such as
shock.